Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill tame childhood cancers that Won't quit?

NCT ID NCT07773454

Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called zanzalintinib in children and teens with solid tumors that have returned or not responded to standard treatment. The main goals are to find the highest safe dose and to see how well the drug is tolerated. Participants receive the drug and are closely monitored for side effects and how the drug moves through their bodies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zanzalintinib (also known as XL092), an oral drug being tested for its safety and tolerability in children with certain cancers
What this could lead to
If successful, this could establish a safe dose of zanzalintinib for children and potentially offer a new treatment option for hard-to-treat pediatric solid tumors.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. The results will only guide further study, not confirm a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 months to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Participants must be \< 17 years old. * Participants must have a minimum body weight of ≥ 10 kilograms (kg) at enrollment. * Performance status of ≥ 50% as measured by Lansky for participants \< 16 years of age or Karnofsky for participants ≥ 16 years of age. * Have a relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma). Key Exclusion Criteria: * For participants with CNS primary tumors, evidence of intracranial or intratumoral hemorrhage are excluded. * Diagnosis of lymphoma. * Lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer cancer childhood malignant neoplasm neoplasm nervous system cancer neuroendocrine neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Pediatric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.